Seegene Unveils Unattended PCR Testing Device at ADLM 2025, Leading Diagnostic Paradigm Shift

Seegene's Revolutionary PCR Automation: A Game Changer in Diagnostics

At the forefront of molecular diagnostics, Seegene Inc. made a significant announcement during the ADLM 2025 (Association for Diagnostics & Laboratory Medicine) conference held in Chicago from July 28 to 31, unveiling the world’s first fully automated unattended PCR testing system, known as CURECA™. This groundbreaking technology is poised to redefine the standards of diagnostic testing globally, presenting a paradigm shift in how laboratories operate.

The Launch of CURECA™

CURECA™ represents a monumental leap in the automation of PCR testing. This innovative system streamlines the entire testing process—from sample storage and preprocessing to nucleic acid extraction, amplification, and analysis—without needing human intervention. Designed for continuous operation, CURECA™ minimizes human error risk, significantly enhancing the accuracy and reliability of test results.

One notable breakthrough within CURECA™ is its fully automated preparatory module. Traditionally, sample preprocessing, especially concerning varied sample types like urine, blood, sputum, and stool, has been fraught with challenges. Laboratory technicians often engage in repetitive manual tasks over extended periods, which can result in inconsistent results due to varying skill levels.

Additionally, stool samples have particularly posed significant challenges due to their viscosity and solid content, previously requiring extensive manual handling. The CURECA™ preparatory module fully automates the preprocessing of all major sample types, including stool, overcoming historical barriers that have hindered laboratory automation. This innovation reduces labor demands, improves sample processing efficiency, and enhances overall laboratory operational efficacy while lowering costs.

Moreover, CURECA™ doesn't exclusively apply to PCR diagnostics; it has versatile applications in clinical chemistry and immunoassay testing. Its modular architecture allows for customizable configurations tailored to the size, layout, and specific needs of any laboratory.

Introducing STAgora™: A Real-Time Data Analysis Platform

In addition to CURECA™, Seegene introduced STAgora™, a groundbreaking statistical platform that collects and analyzes PCR diagnostic data in real-time to inform clinical decision-making. By aggregating test data from hospitals globally, STAgora™ offers integrated insights into regional infection trends and co-infection patterns, equipping healthcare professionals with over 40 customized statistical tools for clinical support.

With STAgora™, healthcare workers can compare individual patient test results against local and regional epidemiological data, fostering the development of more precise, data-driven treatment strategies. This enables physicians to assess infection trends both at patient and community levels, thereby enhancing diagnostic accuracy and care planning efficiency. Through swift and reliable information from comprehensive analysis, STAgora™ could become a vital tool in clinical decision-making.

Expanding Global Collaboration with Strategic Partnerships

At ADLM 2025, Seegene aims to broaden access to its innovative products, CURECA™ and STAgora™, by offering early pilot experiences and establishing new global partnerships. Earlier this year, CURECA™ garnered substantial interest at the ESCMID Global 2025, a leading conference on clinical microbiology and infectious diseases in Europe.

To bolster its research and manufacturing capabilities in the United States, Seegene has established several subsidiaries, such as Seegene Technologies and Seegene CURECA. Daniel Shin, Executive Vice President and Chief Global Sales and Marketing Officer at Seegene, emphasized, “CURECA™ and STAgora™ are more than just diagnostic tools or software; they represent a new global standard that will redefine diagnostics in clinical settings worldwide. We will continue to share our extensive technological resources and drive fundamental innovations within the global diagnostic ecosystem.”

Conclusion

As Seegene sets the stage for the future of diagnostics through its advanced technologies, the potential impact on public health through improved diagnostic accuracy and efficiency is profound. The full commercialization of CURECA™ is currently in its initial stages, with demonstration setups at ADLM 2025 serving exploratory purposes and subject to functional, specification, and component variations in the final commercial version. Seegene's commitment to enhancing the healthcare landscape is supported by over 20 years of expertise in developing real-time PCR diagnostic technologies, contributing significantly during the COVID-19 pandemic by supplying over 340 million tests to more than 100 countries.

For further information, visit Seegene's official website or check out their LinkedIn profile.